Gurtoo H L, Bansal S K, Pavelic Z, Struck R F
Br J Cancer. 1985 Jan;51(1):67-75. doi: 10.1038/bjc.1985.10.
Cyclophosphamide (CP) administration to rats in a single i.p. dose (200 mg kg-1), while producing urinary bladder toxicity and 30-40% depression of the hepatic microsomal mixed function oxidase (MFO), failed to produce any depression of MFO activities in extrahepatic tissues such as lung, kidney and intestine. Phenobarbital pretreatment of the rats, which is known to enhance hepatic microsomal activation of CP, protected against CP-induced urinary bladder toxicity and the depression of hepatic MFO activities. This protection appears to be, at least in part, related to phenobarbital induction of hepatic cytochrome P-450 isozyme(s) that metabolizes CP to a new metabolite tentatively identified as didechlorodihydroxycyclophosphamide.
以单次腹腔注射剂量(200毫克/千克)给大鼠施用环磷酰胺(CP),虽然会产生膀胱毒性并使肝微粒体混合功能氧化酶(MFO)活性降低30 - 40%,但未能使肺、肾和肠等肝外组织中的MFO活性出现任何降低。已知苯巴比妥预处理大鼠可增强肝微粒体对CP的活化,可预防CP诱导的膀胱毒性和肝MFO活性降低。这种保护作用似乎至少部分与苯巴比妥诱导肝细胞色素P - 450同工酶有关,该同工酶将CP代谢为一种新的代谢产物,初步鉴定为双去氯二羟基环磷酰胺。